国产磁性括约肌增强器治疗胃食管反流病23例单中心研究
本研究为前瞻性队列研究,纳入23例胃食管反流病患者,行腹腔镜食管裂孔修补后植入国产磁性括约肌增强器(MSA)。术后消化道总体症状主观缓解程度为90(20)%,总满意率83%(19/23),质子泵抑制剂停药率70%(16/23),反流性食管炎比例由44%(10/23)降至9%(2/23)(P=0.039)。结论认为腹腔镜植入MSA安全、可耐受,能有效控制症状。
要点
- 23例胃食管反流病患者腹腔镜植入国产MSA均成功,未发生装置移位、腐蚀或二次手术移除。
- 术后质子泵抑制剂停药率70%(16/23),总满意率83%(19/23)。
- 反流性食管炎比例由44%(10/23)降至9%(2/23)(P=0.039),21例食管酸暴露恢复正常。
核心结论
- 腹腔镜植入MSA装置安全且患者可耐受,能有效控制胃食管反流病症状、减少用药、恢复贲门形态与功能及食管酸暴露;术后主要并发症为吞咽困难,但较轻微。
研究设计与样本
- 前瞻性队列研究,纳入2019年6月至2022年9月在火箭军特色医学中心胃食管外科就诊的胃食管反流病患者23例,男20例、女3例,年龄48(14)岁(范围25~64岁)。
- 纳入标准为典型烧心和反流症状(至少对质子泵抑制剂有部分反应)、食管酸暴露异常和食管蠕动正常;排除裂孔疝最大径>2 cm和重度食管炎患者。
- 腹腔镜完成食管裂孔修补后将MSA植入食管远端,术后通过问卷评估症状缓解、并发症、质子泵抑制剂停药率和手术满意度,并复查胃镜、食管高分辨率测压和食管pH值-阻抗监测;手术前后率的比较采用McNemar χ2检验。
主要发现
- 主观指标随访17(18)个月(范围14~53个月),客观指标随访17(1)个月(范围12~23个月)。
- 术后消化道总体症状主观缓解程度为90(20)%(范围0~100%),呼吸道总体症状主观缓解程度为100(10)%(范围10%~100%),总满意率83%(19/23),质子泵抑制剂停药率70%(16/23)。
- 反流性食管炎比例由44%(10/23)降至9%(2/23)(κ=0.169,P=0.039),胃食管阀瓣形态Hill分级由术前Ⅰ级1例、Ⅱ级5例、Ⅲ级10例、Ⅳ级7例改善为术后22、1、0、0例。
- 食管下括约肌压力低于正常的比例由70%(16/23)降至35%(8/23)(κ=0.170,P=0.012),21例患者食管酸暴露恢复正常。
- 11例患者存在长期轻度吞咽困难但不影响生活,未发生MSA移位、腐蚀和二次手术移除。
临床怎么用
- 原文结论认为腹腔镜植入MSA操作安全、患者可耐受,可控制胃食管反流病症状、减少用药、恢复正常的贲门形态和功能及食管酸暴露。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To evaluate the safety and efficacy of domestically produced magnetic sphincter augmentation (MSA) for gastroesophageal reflux disease. Method: This study is a prospective cohort study. Patients with typical heartburn and reflux symptoms (at least partial response to proton pump inhibitors), abnormal esophageal acid exposure and normal esophageal peristalsis were included, prospectively in the Department of Gastroesophageal Surgery, Rocket Force Characteristic Medical Center from June 2019 to September 2022. Patients with hiatal hernia >2 cm and severe esophagitis were excluded. The MSA was wrapped around the distal esophagus after esophageal hiatus repair by laparoscopy. A postoperative questionnaire survey was conducted to assess the relief of symptom, complications, the discontinuation rate of proton pump inhibitor, and surgical satisfaction. Gastroscopy, high-resolution esophageal pressure measurement, and pH value impedance monitoring were also reviewed. The pre- and postoperative rates were compared using the McNeinar χ2 test. Result: Currently, 23 patients with gastroesophageal reflux disease were enrolled and underwent MSA surgery. There were 20 males and 3 females, aged (M (IQR)) 48 (14) years (range: 25 to 64 years). All cases were successfully implanted with MSA. Subjective indicators were followed for 17 (18) months (range: 14 to 53 months), while objective indicators were followed for 17 (1) months (range: 12 to 23 months). The postoperative gastrointestinal and extraesophageal symptom scores showed a significant decrease compared to preoperative levels as follows: the degree of subjective relief of overall digestive symptoms was 90 (20)% (range:0~100%), the degree of subjective relief of overall respiratory symptoms was 100(10)% (range: 10%~100%), the overall satisfaction rate was 83% (19/23), the proton pump inhibitor discontinuation rate was 70% (16/23). The proportion of esophagitis has decreased from 44% (10/23) to 9% (2/23) (κ=0.169, P=0.039), The Hill grade of gastroesophageal valve morphology improved from 1 case of grade Ⅰ, 5 cases of grade Ⅱ, 10 cases of grade Ⅲ, and 7 cases of grade Ⅲ preoperative to 22, 1, 0, and 0 cases postoperative. The proportion of lower esophageal sphincter pressure below normal has decreased from 70% (16/23) to 35% (8/23) (κ=0.170, P=0.012). There were 21 patients who restored normal esophageal acid exposure. Eleven patients had mild long-term dysphagia, but it didn't affect their daily life. No postoperative device migration, erosion, or secondary surgical removal occurred. Conclusions: Laparoscopic implantation of the MSA device was safe and well tolerated. It can effectively control the symptoms of gastroesophageal reflux disease, reduce medication, restore normal cardia morphology and function, and esophageal acid exposure. The main postoperative complication was dysphagia, but it was relatively mild. 目的: 评估国产磁性括约肌增强器(MSA)治疗胃食管反流病的安全性和有效性。 方法: 本研究为前瞻性队列研究。前瞻性纳入2019年6月至2022年9月在火箭军特色医学中心胃食管外科就诊的典型烧心和反流症状(至少对质子泵抑制剂有部分反应)、食管酸暴露异常和食管蠕动正常的患者,排除裂孔疝最大径>2 cm和重度食管炎的患者。通过腹腔镜完成食管裂孔修补后将MSA植入食管远端。术后通过问卷了解患者症状缓解情况、并发症、质子泵抑制剂停药率和手术满意度,并复查胃镜、食管高分辨率测压和食管pH值-阻抗监测。手术前后率的比较采用McNemar χ2检验。 结果: 23例患者确诊为胃食管反流病并纳入研究。男性20例,女性3例;年龄[M(IQR)]48(14)岁(范围:25~64岁)。所有病例成功植入MSA。主观指标随访17(18)个月(范围:14~53个月),客观指标随访时间17(1)个月(范围:12~23个月)。术后消化道总体症状的主观缓解程度为90(20)%(范围:0~100%),呼吸道总体症状的主观缓解程度为100(10)%(范围:10%~100%),总满意率为83%(19/23)。质子泵抑制剂停药率为70%(16/23)。反流性食管炎比例由44%(10/23)降至9%(2/23)(κ=0.169,P=0.039),胃食管阀瓣形态Hill分级从术前的Ⅰ级1例、Ⅱ级5例、Ⅲ级10例、Ⅳ级7例,改善为术后的22、1、0、0例。食管下括约肌压力低于正常的比例由70%(16/23)降至35%(8/23)(κ=0.170,P=0.012)。21例患者食管酸暴露恢复正常。11例患者存在长期轻度吞咽困难,但不影响生活。未发生MSA移位、腐蚀和二次手术移除。 结论: 腹腔镜植入MSA操作安全,患者可耐受,可控制胃食管反流病症状,减少用药,恢复正常的贲门形态和功能、食管酸暴露。术后主要并发症为吞咽困难,但较为轻微。.
引用
- Hu ZW, Wu JM, Deng CR, et al. [The effectiveness and safety of the anti gastroesophageal reflux system in the treatment of gastroesophageal reflux disease: a single center study of 23 cases]. Zhonghua Wai Ke Za Zhi. 2024. PMID: 38937126. doi:10.3760/cma.j.cn112139-20240229-00095
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。